- Home
- COLL vs CHI Comparison
COLL vs CHI Comparison
Compare COLL & CHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COLL | CHI |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 968.8M |
| IPO Year | 2015 | 2002 |
Fundamental Metrics
Financial Performance| Metric | COLL | CHI |
|---|---|---|
| Price | $22.99 | $11.11 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $49.00 | N/A |
| AVG Volume (30 Days) | ★ 649.6K | 190.7K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.90% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $780,567,000.00 | N/A |
| Revenue This Year | $6.73 | N/A |
| Revenue Next Year | $1.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 23.62 | N/A |
| 52 Week Low | $21.43 | $10.26 |
| 52 Week High | $50.79 | $13.50 |
Technical Indicators
Market Signals| Indicator | COLL | CHI |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 36.12 |
| Support Level | $21.51 | $11.02 |
| Resistance Level | $23.87 | $11.60 |
| Average True Range (ATR) | 0.75 | 0.29 |
| MACD | 0.28 | -0.01 |
| Stochastic Oscillator | 58.86 | 16.69 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.